Complement-mediated bacteriolysis after binding of specific antibodies to drug-resistant Pseudomonas aeruginosa: Morphological changes observed by using a field emission scanning electron microscope

Journal of Infection and Chemotherapy

Volumn 16, Issue 6, 2010, Pages 383-387

  Tanaka, Jun ^a   Nakae, Takashi ^a   Onoe, Takatoshi ^b   Horiuchi, Yoshitaka ^c   Miyamoto, Hiroyoshi ^a   Adan Kubo, Jun ^a   Adachi, Hiroaki ^b   Ono, Yasuo ^d  

^a Benesis Corporation   (Japan)

^b Southern Osaka University   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

Author keywords

Immune bacteriolysis; Pseudomonas aeruginosa; Scanning electron microscope (SEM)

Indexed keywords

CARBAPENEM; COMPLEMENT COMPONENT C9; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; CELL SURFACE; CONTROLLED STUDY; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; IMAGE ANALYSIS; IMMUNOELECTRON MICROSCOPY; INCUBATION TIME; NONHUMAN; PROTEIN BINDING; PROTEIN DEPLETION; PSEUDOMONAS AERUGINOSA; SERUM BACTERICIDAL ANTIBODY ASSAY; SPHEROPLAST;

EID: 78650858449     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0074-4     Document Type: Article

References (24)

1. National Nosocomial Infection Surveillance System 2004 National nosocomial infection surveillance (NNIS) system report: data summary from January 1992 through June 2004 Am J Infect Control 32 470 485 10.1016/j.ajic.2004.10.001 (Pubitemid 39574472)
2. SA Nouer M Nucci MP de-Oliveira FL Pellegrino BM Moreira 2005 Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase Antimicrob Agents Chemother 49 3663 3667 1:CAS:528:DC%2BD2MXpvFKltL0%3D 16127037 10.1128/AAC.49.9.3663-3667.2005 (Pubitemid 41233015)
3. V Aloush S Navon-Venezia Y Seigman-Igra S Cabili Y Carmeli 2006 Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact Antimicrob Agents Chemother 50 43 48 1:CAS:528:DC%2BD28XivVGmtg%3D%3D 16377665 10.1128/AAC.50.1.43-48.2006 (Pubitemid 43042900)
4. MG Mikolajczyk NF Concepcion T Wang D Fraizer B Golding CE Frasch, et al. 2004 Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations Clin Diagn Lab Immunol 11 1158 1164 1:CAS:528:DC%2BD2cXhtFShsrvO 15539522
5. M Pollack 1983 Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans J Infect Dis 147 1090 1098 1:CAS:528:DyaL3sXkvVKgs7g%3D 6406615
6. T Nakae F Hirayama M Hashimoto 2002 Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1 Kansenshogaku Zasshi 76 195 202 11974889
7. A Norrby-Teglund H Basma J Andersson A McGeer DE Low M Kotb 1998 Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy Clin Infect Dis 26 631 638 1:CAS:528:DyaK1cXhvVyltbo%3D 9524835 10.1086/514588
8. C Yanagisawa H Hanaki T Natae K Sunakawa 2007 Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin J Infect Chemother 13 368 372 1:CAS:528:DC%2BD2sXhsVGgtL3L 18095084 10.1007/s10156-007-0551-6 (Pubitemid 350308154)
9. T Masaoka H Hasegawa F Takaku H Mizoguchi S Asano Y Ikeda, et al. 2000 The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections Jpn J Chemother 48 199 217
10. Y Ono T Ito T Watanabe O Koshio S Tansho T Ikeda, et al. 2004 Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria J Infect Chemother 10 234 238 1:CAS:528: DC%2BD2cXnsVCisL0%3D 15365865
11. T Nakae J Tanaka A Nakano Y Ono 2008 Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant Pseudomonas aeruginosa Jpn J Antibiot 61 379 387 1:CAS:528: DC%2BD1MXmsVensQ%3D%3D 19288855 10.1038/ja.2008.53
12. M Fujita M Matsushita Y Endo 2004 The lectin-complement pathway: its role in innate immunity and evolution Immunol Rev 198 185 202 1:CAS:528: DC%2BD2cXjs1yjsrw%3D 15199963 10.1111/j.0105-2896.2004.0123.x (Pubitemid 38406944)
13. D Mastellos D Morikis SN Isaacs MC Holland CW Strey JD Lambris 2003 Complement: structure, functions, evolution, and viral molecular mimicry Immunol Res 27 367 386 1:CAS:528:DC%2BD3sXmvFyhsLg%3D 12857982 10.1385/IR:27:2-3:367 (Pubitemid 36995019)
14. CJ Rosado AM Buckle RH Law RE Butcher WT Kan CH Bird, et al. 2007 A common fold mediates vertebrate defense and bacterial attack Science 317 1548 1551 1:CAS:528:DC%2BD2sXhtVejt7%2FM 17717151 10.1126/science.1144706 (Pubitemid 47417433)
15. J Tschopp D Masson KK Stanley 1986 Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis Nature (Lond) 322 831 834 1:CAS:528:DyaL2sXhtVSmsLs%3D 10.1038/322831a0
16. RG DiScipio TE Hugli 1985 The architecture of complement component C9 and poly(C9) J Biol Chem 260 14802 14809 1:CAS:528:DyaL2MXlvFCltbY%3D 4055801
17. RG DiScipio C Berlin 1999 The architectural transition of human complement component C9 to poly(C9) Mol Immunol 36 575 585 1:CAS:528: DyaK1MXlslShu70%3D 10499811 10.1016/S0161-5890(99)00073-5 (Pubitemid 29395555)
18. SR Nusinow BL Zuraw JG Curd 1985 The hereditary and acquired deficiencies of complement Med Clin N Am 69 487 504 1:STN:280:DyaL2M3jvFagsg%3D%3D 3892188
19. M Trautmann M Heinemann R Zick A Möricke M Seidelmann D Berger 1998 Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects Eur J Clin Microbiol Infect Dis 17 754 760 1:CAS:528:DyaK1MXjtVyjtg%3D%3D 9923514 10.1007/s100960050180 (Pubitemid 29219126)
20. T Horii M Kobayashi K Sato S Ichiyama M Ohta 1998 An in vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli J Antimicrob Chemother 41 435 442 1:CAS:528:DyaK1cXisV2qurc%3D 9598774 10.1093/jac/41.4.435 (Pubitemid 28167502)
21. Y Sumita S Tada H Nouda T Okuda M Fukasawa 1992 Mode of action of Meropenem, a new carbapenem antibiotic Eur J Immunol 24 90 102
22. J Tschopp A Engel ER Podack 1984 Molecular weight of poly(C9): 12 to 18 C9 molecules form the transmembrane channel of complement J Biol Chem 259 1922 1928 1:CAS:528:DyaL2cXhtF2is78%3D 6319415
23. U Skansén-Saphir J Andersson L Björk C Ekberg TE Fehniger JI Henter, et al. 1998 Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells Scand J Immunol 47 229 235 9519861 10.1046/j.1365-3083.1998.00299.x (Pubitemid 28153400)
24. B Cao H Wang H Sun Y Zhu M Chen 2004 Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections J Hosp Infect 57 112 118 1:STN:280:DC%2BD2c3osVSlsA%3D%3D 15183240 10.1016/j.jhin.2004. 03.021 (Pubitemid 38745423)